3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Wilms Tumor
2
Sarcoma, Ewing
2
Sarcoma
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Glioma
2
Ependymoma
2
Xanthogranuloma, Juvenile
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Pheochromocytoma
1
Melanoma
1
Histiocytic Sarcoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Central Nervous System Neoplasms
1
Interventions
pembrolizumab
59
Carboplatin
56
Pemetrexed
47
Cisplatin
39
Paclitaxel
24
Nivolumab
23
Docetaxel
21
durvalumab
20
Gemcitabine
15
130-nm albumin-bound paclitaxel
14
osimertinib
13
Cetuximab
12
Specimen Handling
11
Magnetic Resonance Spectroscopy
11
atezolizumab
10
amivantamab
8
Taxes
8
Radiotherapy
8
Radiosurgery
7
Ipilimumab
7
lazertinib
6
alectinib
6
Ramucirumab
6
Observation
6
Bevacizumab
6
cemiplimab
5
Leucovorin
5
Fluorouracil
5
Etoposide
5
Erlotinib Hydrochloride
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Non-Small-Cell Lung
×
tipifarnib
×
30 days
×
Clear all
No trials found.